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ABSTRACT
Adenovirus-mediated sensitization of cancer cells to cytotoxic drugs depends on 
simultaneous interactions of early viral genes with cell death and survival pathways. 
It is unclear what cellular factors mediate these interactions in the presence of DNA-
damaging drugs. We found that adenovirus prevents Chk1-mediated checkpoint 
activation through inactivation of Mre11 and downregulation of the pChk1 adaptor-
protein, Claspin, in cells with high levels of DNA-damage induced by the cytotoxic 
drugs gemcitabine and irinotecan. The mechanisms for Claspin downregulation involve 
decreased transcription and increased degradation, further attenuating pChk1-
mediated signalling. Live cell imaging demonstrated that low doses of gemcitabine 
caused multiple mitotic aberrations including multipolar spindles, micro- and multi-
nucleation and cytokinesis failure. A mutant virus with the anti-apoptotic E1B19K-
gene deleted (Ad∆19K) further enhanced cell killing, Claspin downregulation, and 
potentiated drug-induced DNA damage and mitotic aberrations. Decreased Claspin 
expression and inactivation of Mre11 contributed to the enhanced cell killing in 
combination with DNA-damaging drugs. These results reveal novel mechanisms that 
are utilised by adenovirus to ensure completion of its life cycle in the presence of 
cellular DNA damage. Taken together, our findings reveal novel cellular targets that 
may be exploited when developing improved anti-cancer therapeutics.
INTRODUCTION
Replication-selective oncolytic adenoviral mutants 
are promising as future cancer therapeutics because of 
their efficient lysis of a broad range of adenocarcinoma 
types, including drug-resistant cancers, with demonstrated 
clinical safety [1, 2]. Most studies have employed mutants 
based on adenovirus serotype 5 of species C (Ad5), which 
has a small 36kb linear dsDNA genome enclosed by a 
protein capsid [3]. Cellular entry occurs via attachment to 
Coxsackie virus and adenovirus receptor (CAR), and αvβ3 
and αvβ5 integrins for endosome-mediated internalisation 
and capsid degradation, followed by transport of viral 
DNA to the nucleus for expression of early viral genes. To 
support viral DNA and protein synthesis, the early viral 
E1A gene-products inactivate the G1/S checkpoint, mainly 
through inhibition of pRb, leading to E2F-mediated 
transcription of S-phase genes, which is essential for the 
viral life cycle [4]. To avoid elimination of the infected 
cells by cellular defence mechanisms, the early viral E1B, 
E3 and E4 gene-products act to inhibit apoptosis, immune 
response activation and DNA-damage repair. These viral 
functions have been exploited to engineer oncolytic 
mutants that are unable to propagate in normal cells but 
efficiently replicate in cancer cells with deregulated cell 
survival and apoptosis pathways [1, 2]. Currently, the 
clinically most efficacious replication-selective mutants 
harbour a small deletion of the E1ACR2-domain (e.g. 
dl922-947 and Ad∆24) to ablate pRb-binding that results 
in potent anti-tumour efficacy in various solid tumours 
with deregulated cell cycle and limited toxicity to normal 
tissue (e.g. [5, 6]). To date, significant clinical responses 
have only been reported in combination with cytotoxic 
drugs and/or radiation therapy [1, 5, 7-9].
In preclinical models, efficacy of viruses has been 
clearly demonstrated both when administered alone and in 
combination with conventional therapeutics. For example, 
potent synergistic cancer cell killing was demonstrated 
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with several oncolytic adenoviruses in combination 
with DNA-damaging agents, including gemcitabine and 
irinotecan [10-13]. However, the cellular mechanisms 
for the increased tumour cell killing in combination with 
drugs are mostly unknown, both in preclinical models and 
in patients. Virus-induced cell lysis occurs through non-
apoptotic, necrotic-like cell death mechanisms while in 
combination with cytotoxic drugs, drug-induced apoptosis 
is often enhanced [11, 14-16]. It has been established 
that viral E1A expression is necessary for synergistic 
enhancement of cytotoxic drug-induced cell death and that 
E1A-binding to p300 and p400 is required, but not to pRb 
[14, 17-19]. Furthermore, the E4orf3 and E4orf6 genes 
are rapidly expressed after infection to prevent the cellular 
DNA-damage response (DDR) mainly by inactivating the 
Mre11-Rad50-Nbs1 (MRN) complex [20, 21]. E4orf3 
sequesters the Mre11 subunit to nuclear tracks and 
E4orf6 together with E1B55K targets Mre11, Nbs1 and 
p53 for proteasomal degradation, resulting in checkpoint 
abrogation [20, 22, 23]. These functions are likely to 
contribute to the enhanced cell killing in combination with 
DNA-damaging drugs.
To take advantage of the virus-mediated 
enhancement of cancer cell killing in combination with 
DNA-damaging drugs we developed mutants with the 
anti-apoptotic E1B19K gene deleted in addition to 
tumour-selective deletions including the E1ACR2-domain 
(e.g. Ad∆∆) [11, 24, 25]. E1B19K is a functional Bcl-2 
homologue that binds Bax and Bak, therefore inhibiting 
mitochondrial pore formation and apoptosis in response 
to both death receptor–induced signaling and intrinsically 
induced apoptosis (p53-dependent and -independent) 
[26-29]. Our approach to eliminate E1B19K rather than 
the anti-apoptotic p53-binding E1B55K (e.g. Onyx-015, 
H101), which greatly attenuates viral production, resulted 
in mutants with retained high potency in models of 
pancreatic and prostate cancers [11, 24]. Both Ad∆19K 
and Ad∆∆ greatly enhanced cell killing induced by the 
DNA-damaging agents gemcitabine and irinotecan [10, 
11], which are currently being used for the treatment of 
pancreatic cancers.
In the current study, we employed Ad∆19K (deleted 
only in E1B19K) to identify virus-dependent mechanisms 
that converge on drug-induced signalling pathways 
to confer cell death of pancreatic cancer cells. We 
demonstrate that AdΔ19K cooperates with gemcitabine 
or irinotecan to deregulate cell-cycle mechanisms. 
For the first time, we report that adenovirus attenuates 
Chk1 activation even in the presence of cytotoxic drugs 
and high levels of DNA damage. We demonstrate that 
Ad∆19K inactivates the DNA repair factor Mre11 and 
prevents drug-induced accumulation of Claspin, a protein 
required for Chk1 activation. These findings identify 
novel mechanisms for virus-mediated weakening of the 
DDR, followed by increased mitotic aberrations and cell 
death, as causes of the virus-mediated drug-sensitization. 
We conclude that Claspin and associated regulatory factors 
including Mre11 and Chk1 could be therapeutically 
targeted by E1B19K-deleted oncolytic viruses and/or 
novel inhibitors to better manage treatment-insensitive 
pancreatic cancers in particular.
RESULTS
The adenoviral mutant Ad∆19K synergises 
with gemcitabine and irinotecan by enhancing 
apoptotic death in pancreatic cancer cells
We previously demonstrated that E1B19K-deleted 
mutants cause potent synergistic cell death in combination 
with several cytotoxic drugs including gemcitabine [10, 
11]. To investigate the mechanisms of action in the current 
study we first assessed cell death over time in response 
to low doses of Ad5 and AdΔ19K in combination with 
gemcitabine or irinotecan in the pancreatic cancer cells 
PT45 and MIAPaCa2. In PT45, the combination of 
AdΔ19K with gemcitabine induced significantly more 
cell death than each agent alone at 72 through 96h post-
treatment (Figure 1a). Similar results were obtained with 
irinotecan. Cell death with gemcitabine and Ad∆19K 
was synergistic and higher than the combination with 
Ad5 at 48 - 96h (Figure 1a and Table S1). In MIAPaCa-2 
cells, cell killing was also increased with Ad∆19K in 
combination with either drug (Figure 1b and Table S1). 
In accordance, significantly higher sensitization ratios 
were observed when suboptimal doses of AdΔ19K were 
combined with gemcitabine or irinotecan compared to Ad5 
in cell viability assays, in both PT45 and MIAPaCa2 cells 
(Figure 1c). We confirmed that the enhanced cell killing 
occurred through caspase-3-dependent apoptosis that was 
significantly greater in Ad∆19K-infected gemcitabine-
treated cells compared to all other treatments (Figure 1d). 
Ad5 in combination with gemcitabine also induced 
caspase-3–dependent apoptosis that was significantly 
higher than the corresponding single agent-treatments. 
Interestingly, the majority of apoptosis occurred in cells 
with a DNA content of 4N and >4N, which mainly 
represent cells in G2/M phases (Figure 1d). There were 
significantly more apoptotic cells with 4N DNA content 
when AdΔ19K was combined with gemcitabine compared 
to the drug treatment alone. In contrast to AdΔ19K, 
which caused apoptosis mostly in cells with >4N DNA 
content, gemcitabine caused apoptosis equally in cells 
occupying G1, S and G2/M phases and the presence of 
AdΔ19K promoted the apoptosis of cells in G2/M phases 
(Figure 1d). Similar trends were observed in Ad5-infected 
cells.
These findings demonstrate that the synergistic 
cell killing in Ad∆19K-infected drug-treated cells occurs 
through more potent caspase-3-dependent apoptosis 
than in Ad5-infected cells. Furthermore, the enhanced 
cell killing is independent of viral DNA replication, 
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Figure 1: The adenoviral mutant Ad∆19K synergises more potently than Ad5 with gemcitabine and irinotecan by 
enhancing apoptotic death in pancreatic cancer cells. a and b. Cell death assays using Trypan blue dye incorporation in PT45 
(a) and MIAPaCa-2 (b) cells. Error bars represent S.E.M. of A. 3-7 and B. 3-4 independent experiments. c. Sensitization ratios (EC50 of 
virus / EC50 of virus and drug) derived from cell viability assays in PT45 (left panel) and MIAPaCa-2 (right panel) cells. Red dotted lines 
indicate a ratio of 1 (= no sensitization). Drug cytotoxicity (%) ± S.E.M. was: 40.3±5.8% and 30.7±10.7% with 2nM (PT45) and 10nM 
(MIAPaCa-2) gemcitabine (Gem), respectively, and 28.0±2.1% and 34.3±8.6% with 3μM (MIAPaCa-2) and 5μM (PT45) irinotecan (Iri), 
respectively. Error bars represent S.E.M. of 4 independent experiments. d. Percentage of apoptotic cells (total apoptosis, left panel) as 
determined by cleaved caspase-3 flow-cytometric assays in PT45 cells. Apoptosis in each cell-cycle phase/DNA content (right panel) is 
expressed as % of total apoptosis in each condition. Error bars represent S.E.M. of 3 independent experiments. a-d. *.p<0.05, **.p<0.01, 
***.p<0.001 (one-way ANOVA with Bonferroni's multiple comparison test).
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demonstrated by prevention of both viral DNA 
amplification and assembly of viral replication centres 
(Figure S1a-b). In contrast, more adenovirus-infected 
E1A-positive cells were detected in gemcitabine-treated 
PT45 and MIAPaCa-2 cells, an increase that occurred 
earlier in Ad∆19K-infected cells and was paralleled by 
higher E1A mRNA levels (Figure S1c-d).
Adenovirus increases the mitotic index and 
aberrant mitosis in gemcitabine-treated cells
Based on our findings that more apoptotic cells 
accumulated in G2/M phases we hypothesised that 
cell cycle progression was required after gemcitabine-
induced S-phase arrest for virus to enhance cell killing. 
To monitor cell cycle progression following treatment, 
we synchronised cells using thymidine block and 
performed cell cycle and mitotic index analysis over 
time, with E1A as a marker of infected cells. As expected, 
gemcitabine induced S-phase arrest that peaked at 36h; 
this was followed by cell progression to G2 and a gradual 
G1 arrest (Figure 2a, statistics in Table S2). AdΔ19K 
infection did not affect drug-induced S-phase arrest, 
however, the gradual gemcitabine-dependent G1 arrest 
(48-72h) was prevented by virus and cells accumulated 
in S and G2 phases (Figure 2a). In non-synchronised 
PT45 and MIAPaCa-2 cells gemcitabine-induced S-phase 
arrest was also unaffected by adenovirus infection and 
cells accumulated in S and G2/M phases (Figure S2a-b). 
Similarly, AdΔ19K did not interfere with irinotecan-
induced S/G2 arrest (Figure S2c). Interestingly, mitotic 
index analysis in synchronised PT45 cells revealed that 
adenovirus infection significantly increased the mitotic 
index of gemcitabine-treated cells following the drug-
induced S-phase block (Figure 2b).
The observation that virus-infection of gemcitabine-
treated cells resulted in a higher proportion of cells 
accumulating in the G2/M phase, prompted us to 
investigate whether these cells displayed normal or 
aberrant mitosis. We found that gemcitabine-treated cells 
exhibited significantly increased spindle multipolarity 
in mitosis, as determined by immunofluorescence 
microscopy of the spindle pole marker Aurora A (Figure 
2c). Further increases were seen in the presence of either 
Ad5 or AdΔ19K (Figure 2c), which can be attributed to 
E1A-induced centrosome amplification [30]. Multipolar 
spindles were also abundant in irinotecan treated cells 
(Figure S2d). Since there were no major differences 
in effect on mitosis and multipolarity between Ad5 or 
Ad∆19K in combination with gemcitabine we pursued 
further in depth studies using the Ad∆19K mutant. 
Analysis of mitotic progression was performed using long-
term time-lapse microscopy of synchronised histone H2B 
mCherry-expressing PT45 cells. Gemcitabine treatment 
resulted in prolonged mitosis (2.9±1.5h), which was 
unaffected by AdΔ19K infection (3.2±1.1h) (Figure 2d 
and S2e). Spindle multipolarity was evident following 
gemcitabine treatment and resulted in multipolar 
divisions (42.9±10.6%), with more multipolar anaphases 
in the presence of AdΔ19K (63.4±6.8%) (Figure 2e). 
Moreover, gemcitabine treatment induced cytokinesis 
failure (15.3±8.8%), which was promoted by AdΔ19K 
(31.1±11.4%) (Figure 2f). As a consequence of the 
aberrant mitotic progression, a high degree of micro- and 
multi-nucleated daughter cells was observed (Figure 2g) 
that was likely a result of chromosome alignment and 
segregation errors. Addition of AdΔ19K significantly 
decreased the frequency of mononucleated cells and 
consequently increased occurrence of multinucleation in 
combination-treated cells compared to gemcitabine alone 
(Figure 2g).
We conclude that following the S-phase arrest, 
gemcitabine-treated cells went through a prolonged 
aberrant mitosis and that AdΔ19K infection did not 
affect the initial drug-induced S-phase arrest nor mitotic 
duration but promoted mitotic entry, spindle multipolarity, 
cytokinesis failure and multinucleation. Moreover, 
Ad∆19K prevented gemcitabine-treated PT45 cells from 
accumulating in G1 with more cells remaining in the S and 
G2/M phases, suggesting that combination-treated cells 
were non-viable and died before entering G1.
AdΔ19K and DNA-damaging drugs cooperate to 
increase cellular DNA damage
Despite the accumulation of mitotic aberrations as 
a consequence of viral infection of gemcitabine-treated 
cells, the total number of cells in mitosis (<12%) could 
not account for the significantly increased synergistic 
cell killing. Both gemcitabine and irinotecan cause 
DNA damage [31-33] and adenovirus has been reported 
to induce host cell DNA strand breaks [34, 35]. To 
investigate whether DNA-damage and repair mechanisms 
also contributed to the synergistic cell killing, we explored 
whether Ad∆19K and/or Ad5 enhanced drug-induced 
DNA-damage. The degree of DNA strand breaks was 
determined by terminal dUTP nick end labelling (TUNEL) 
assays and signals were quantified only in cells with a 
DNA content of 2N-4N, in order to exclude cells with 
fragmented DNA (apoptotic DNA fragmentation). The 
frequency of TUNEL-positive cells was significantly 
elevated in cells treated simultaneously with AdΔ19K 
and gemcitabine, compared to either agent alone or the 
combination of Ad5 with gemcitabine (Figure 3a).
To verify the presence of DNA damage, we 
assessed the expression levels of the DNA damage marker 
H2AX phosphorylation over time by immunoblotting 
followed by densitometric quantification. In PT45 cells 
the combination of AdΔ19K with either gemcitabine or 
irinotecan caused significantly higher levels of H2AX 
phosphorylation at 48 and 72h post-treatment, compared 
to the corresponding single agent treatments (Figure 3c). 
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Figure 2: Adenovirus increases the mitotic index in gemcitabine-treated cells and enhances aberrant passage through 
mitosis. a and b. Cell cycle and mitotic index analysis in synchronised PT45 cells, stained with propidium iodide (for DNA-content 
analysis), a phospho-histone H3 antibody (for mitotic index analysis) and an E1A antibody (for identification of infected cells) and analysed 
by flow-cytometry. Dead cells, as identified from their incorporation of FVD, and cells in subG1 phase were excluded from the analysis. 
a. Cell-cycle distribution of non-infected or infected cells, shown as % cells in G1-phase, S-phase, G2-phase and mitosis (M). Only 
S-phase statistical significance is shown. b. Mitotic Index (% cells in mitosis). Error bars represent S.E.M. of 4 independent experiments. 
c. Immunofluorescence microscopy analysis of Aurora-A (green) and α-Tubulin (red) with nuclear DAPI staining (DNA, blue) in PT45 
cells fixed at 48hpi using methanol. Left panel: Example images of bipolar and multipolar spindles in cells treated with gemcitabine. Scale 
bar: 5μm. Right panel: Quantification of spindle multipolarity, expressed as frequency (%), ≥ 150 mitotic cells/condition were counted. 
Error bars represent S.E.M of two independent experiments. d-g. Time-lapse microscopy 24-96hpi in PT45 cells stably expressing histone 
H2B-mCherry. Error bars represent S.E.M of 3 independent experiments. Numbers on images indicate time (in minutes). Scale bar: 20μm. 
d. Scatter plot showing the duration of mitosis, defined from the time of nuclear envelope breakdown until the time of sister chromatid 
separation. At least 100 mitotic cells were analysed/condition/study in 3 independent studies.
(Continued )
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Figure 2 (Continued  ): e. Frequency (%) (top panel) and example images (bottom panels) of bipolar and multipolar anaphases. At 
least 100 mitotic cells were analysed/condition/study in 3 independent studies. f. Frequency (%) (top panel) and example images (bottom 
panels) of cytokinesis failure. At least 100 mitotic cells were analysed/condition/study in 3 independent studies. g. Frequency (%) (top 
panel) and example images (bottom panels) of mononucleated, micronucleated and multinucleated daughter cells. At least 150 daughter 
cells were analysed/condition/study in 3 independent studies. a-g. *.p<0.05 **.p<0.01, ***.p<0.001 (one-way ANOVA with Bonferroni’s 
multiple comparison test)
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Figure 3: AdΔ19K and DNA-damaging drugs cooperate to induce DNA damage. a. TUNEL flow-cytometric assay for DNA 
strand breaks 72hpi in PT45 cells. Error bars represent S.E.M. of 2-4 independent experiments. Only cells with a DNA content of 2-4N 
were analysed. b. Immunofluorescence microscopy analysis of E1A (green) and γH2AX (red) with nuclear DAPI staining (DNA, blue) 
in PT45 cells fixed at 48hpi using paraformaldehyde. Representative images of 3 independent experiments are shown. Scale bar: 20μm 
c. Immunoblot analysis of phospho-histone H2AX (Ser139) (pH2AX) in PT45 cells, treated with 300ppc viruses ± 5nM gemcitabine 
(Gem) (left panel) and 5μM irinotecan (Iri) (right panel). Upper panels: Representative immunoblots of pH2AX (15kDa) with α-Tubulin 
(55kDa) or Actin (42kDa) as loading controls. Numbers indicate MW size marker (kDa). Vertical lines on the immunoblot indicate points 
of cropping. Bottom panels: pH2AX protein levels were quantified by densitometric analysis, normalised to the loading control and 
expressed as fold-change relative to mock 24h (=1). Error bars represent S.E.M. of 3 independent experiments. a-c.*.p<0.05 **.p<0.01, 
***.p<0.001 (one-way ANOVA with Bonferroni's multiple comparison test).
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At 72h, the combination of Ad5 with irinotecan, but 
not gemcitabine, also induced more phospho-H2AX 
expression than the single agent treatments (Figure 3c). 
The increased levels of phospho-H2AX in PT45 cells 
treated with either gemcitabine or AdΔ19K were observed 
as distinct foci in cells expressing the viral E1A protein 
determined by immunofluorescence microscopy (48h; 
Figure 3b). Similar results were obtained in MIAPaCa-2 
cells 48h post-treatment (Figure S3). Therefore, the 
E1B19K deletion confers earlier and more potent 
induction of DNA damage in combination with DNA-
damaging drugs compared to the intact Ad5 virus.
AdΔ19K attenuates the DNA damage response 
induced by gemcitabine and irinotecan
The presence of high levels of DNA damage and 
the abnormal mitosis led us to investigate drug- and 
virus-mediated effects on the DNA damage response by 
determining changes in activation of the checkpoint kinase 
Chk1. In PT45 cells, gemcitabine and irinotecan induced 
Chk1 phosphorylation that subsided from 24 to 72h post-
treatment (Figure 4a), while in MIAPaCa-2 cells drug-
induced Chk1 phosphorylation peaked at 48h (Figure S4a). 
As expected, no phosphorylation of Chk1 was observed 
upon infection with either Ad5 or Ad∆19K. Drug-induced 
Chk1 phosphorylation was overall attenuated in the 
presence of virus in both cell lines (Figure 4a and S4a). 
Significantly decreased Chk1 phosphorylation in PT45 
cells was observed with AdΔ19K 24h after treatment 
with either drug, while Ad5 significantly attenuated only 
gemcitabine-induced Chk1 phosphorylation at 24h (Figure 
4a). In MIAPaCa-2 cells, AdΔ19K-mediated attenuation 
of drug-induced Chk1 phosphorylation was noted 48h 
after treatment (Figure S4a).
Immediately after adenovirus infection, the 
DDR is prevented by viral early proteins that act by 
mislocalising and degrading the MRN complex [23]. To 
determine whether Ad∆19K also reduced drug-induced 
Chk1 phosphorylation through the same mechanisms, 
we examined Mre11 localisation and expression in 
combination-treated cells. In untreated and gemcitabine-
treated cells, diffuse pan-nuclear localisation of Mre11 
was observed (Figure 4b). In striking contrast, AdΔ19K-
infected cells mislocalised Mre11 in track-like structures 
and reduced Mre11 expression, regardless of the presence 
of gemcitabine (right panels, E1A+/Mre11+ cells; Figure 
4b). Immunoblotting verified that Mre11 expression 
was significantly reduced (Figure 4c), consistent with 
adenovirus-dependent degradation of Mre11. Importantly, 
the downregulation of Mre11 was still evident in the 
presence of either gemcitabine or irinotecan (Figure 
4c). In PT45 cells infected with AdΔ19K, Mre11 protein 
levels were significantly lower 24-72h after gemcitabine-
treatment and 48-72h after irinotecan-treatment, compared 
to drug alone (Figure 4c). Significantly lower Mre11 levels 
were also noted after 48-72h with Ad5 in combination 
with gemcitabine. In MIAPaCa-2 cells, significant 
reductions in Mre11 expression compared to drug alone 
were detected 24-48h post-treatment with AdΔ19K and 
either gemcitabine or irinotecan, and 24h post-treatment 
with Ad5 in combination with irinotecan (Figure S4b). 
To conclude, AdΔ19K mislocalised and degraded Mre11 
even in the presence of DNA-damaging drugs, inactivating 
the MRN complex and consequently attenuating Chk1 
activation and the DNA damage and repair signalling.
AdΔ19K inhibits drug-induced accumulation 
of Claspin through increased degradation and 
decreased synthesis
The findings that AdΔ19K promoted drug-induced 
DNA-damage and attenuated DDR signalling, suggested 
that the diminished activation of Chk1 played a role in 
the enhanced cell killing. In response to replication 
stress or DNA damage, Chk1 is activated by ATR-
mediated phosphorylation through recruitment of the 
adaptor protein Claspin [36, 37]. We found that both 
gemcitabine and irinotecan induced the accumulation 
of Claspin at 24-48h post-treatment in PT45 (Figure 5a) 
and MIAPaCa2 cells (Figure S5a). Interestingly, in PT45 
cells both gemcitabine- and irinotecan-induced Claspin 
accumulation was significantly reduced in the presence of 
AdΔ19K, but not with Ad5 (Figure 5a). In MIAPaCa-2 
cells similar effects were observed in the presence of 
AdΔ19K (Figure S5a).
For cells to efficiently recover from the ATR/Chk1 
checkpoint response and enter mitosis, Claspin needs to be 
degraded by a mechanism involving the ubiquitin ligase 
complex β-TrCP-SCF, Aurora-A and Plk-1 [38, 39]. Since 
we had observed that Ad∆19K-infection of gemcitabine-
treated cells decreased pChk1 levels, increased the mitotic 
index and reduced drug-induced Claspin accumulation, 
we asked whether virus promoted Claspin degradation. To 
address this question we examined Plk1 phosphorylation, 
a major protein responsible for phosphorylating and 
targeting Claspin for ubiquitination and subsequent 
proteasomal degradation [39]. In PT45 cells, AdΔ19K, 
but not Ad5, significantly induced Plk1 phosphorylation 
48h post-infection (Figure 5b). No significant changes 
in pPlk1 were observed in cells treated with gemcitabine 
alone. In Ad∆19K-infected cells Plk1 phosphorylation was 
still maintained, albeit to a lesser extent, in the presence 
of gemcitabine and was significantly higher compared to 
gemcitabine alone or in combination with Ad5 (Figure 
5b). Similar results were obtained with irinotecan (Figure 
5b). Analogous to PT45 cells, the presence of AdΔ19K 
in gemcitabine-treated MIAPaCa-2 cells significantly 
induced the levels of pPlk1 (Figure S5b). Hence AdΔ19K-
induced phosphorylation of Plk1 persisted, albeit to a lesser 
extent, in the presence of chemotherapeutic drugs. To 
further investigate whether increased pPlk1 led to Claspin 
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Figure 4: AdΔ19K attenuates the DNA damage response induced by gemcitabine and irinotecan. a. Immunoblot analysis of 
phospho-Chk1 (Ser296) (pChk1) and total Chk1 in PT45 cells, treated with 300ppc viruses ± 5nM gemcitabine (Gem) (left panel) and 5μM 
irinotecan (Iri) (right panel). Upper panels: Representative immunoblots of phospho- and total Chk1 (56kDa) with Vinculin (130kDa) 
as loading control. Numbers indicate MW size marker (kDa). Vertical lines on the immunoblot indicate points of cropping. Bottom 
panels: pChk1 protein levels were quantified by densitometric analysis, normalised to total Chk1 and the loading control and expressed 
as fold-change relative to mock 24h (=1). Error bars represent S.E.M. of 3 independent experiments. b. Immunofluorescence microscopy 
analysis of E1A (green) and Mre11 (red) with nuclear DAPI staining (DNA, blue) in PT45 cells, fixed at 24hpi using paraformaldehyde. 
Representative images of 2 independent experiments are shown. Scale bar: 20μm.
(Continued )
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degradation in the presence of Ad∆19K we determined 
Claspin half-life by cycloheximide-chase assays. The half-
life of Claspin was significantly reduced in gemcitabine-
treated cells in the presence of AdΔ19K compared to 
untreated cells (Figure 5c). However, the shorter half-life 
was unlikely to cause the significant downregulation of 
Claspin levels observed in combination-treated cells and 
we explored whether Claspin synthesis was also decreased. 
Claspin mRNA levels were increased in the presence of 
gemcitabine (Figure 5d), likely a consequence of drug-
induced S-phase arrest. Remarkably, AdΔ19K- but not 
Ad5-infection of gemcitabine-treated cells significantly 
decreased Claspin mRNA levels to almost basal after 
48h (Figure 5d). In addition, when protein degradation 
was prevented by the proteasomal inhibitor MG-132 
newly-synthesised Claspin accumulated in cells treated 
with gemcitabine alone but not in cells treated with a 
combination of gemcitabine and AdΔ19K (Figure 5e). 
This confirmed that gemcitabine-induced upregulation of 
Claspin synthesis was inhibited in the presence of AdΔ19K.
Mre11 and Claspin knockdown enhance cell 
death and DNA damage induced by AdΔ19K and 
DNA-damaging drugs
In order to determine whether the AdΔ19K-
dependent downregulation of Claspin and Mre11 in the 
presence of chemotherapeutic drugs was essential for 
the enhanced cell killing in response to the combination 
treatment, we silenced both Claspin and Mre11. 
Knockdown efficiency in PT45 cells transfected with 
Claspin or Mre11 siRNA ranged from 46-58% for Claspin 
and from 72-78% for Mre11, at 72-120h post-transfection 
(Figure 6a-6b). Silencing of either Claspin or Mre11 
increased the sensitization ratios in cells treated with 
gemcitabine or irinotecan and AdΔ19K, as compared to 
non-targeting siRNA (Figure 6a-6b; lower panels). We 
verified that cell death was significantly increased in cells 
with knockdown of either Claspin or Mre11 in response 
to the AdΔ19K and gemcitabine combination at 48 and 
72h post-treatment, compared to non-targeted knockdown 
(Figure 6c). In addition, AdΔ19K infection alone but not 
gemcitabine treatment alone resulted in greater cell death 
72h after infection in the knockdown cells (Figure 6c). 
Interestingly, AdΔ19K DNA replication was increased 
in cells transfected with Mre11 but not Claspin siRNA 
(Figure 6d). However, in the presence of gemcitabine, 
viral replication was greatly attenuated in cells treated 
with any of the siRNAs (Figure 6d). These data are in 
agreement with our sensitization studies demonstrating 
that the increased cell death was not due to enhanced viral 
replication (Figure 1a-1b, Figure S1a-b).
Next we investigated whether Claspin and Mre11 
silencing in combination-treated cells was accompanied 
Figure 4 (Continued  ): c. Immunoblot analysis of Mre11 in PT45 cells, treated with 300ppc viruses ± 5nM gemcitabine (Gem) (left 
panel) and 5μM irinotecan (Iri) (right panel). Upper panels: Representative immunoblots of Mre11 (81kDa) with α-Tubulin (55kDa) as 
loading control. Numbers indicate MW size marker (kDa). Vertical lines on the immunoblot indicate points of cropping. Bottom panels: 
Mre11 protein levels were quantified by densitometric analysis, normalised to the loading control and expressed as fold-change relative to 
mock 24h (=1). Error bars represent S.E.M. of at least 3 independent experiments. a-c. *.p<0.05 **.p<0.01, ***.p<0.001 (one-way ANOVA 
with Bonferroni’s multiple comparison test).
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by increased DNA damage and/or effects on cell-cycle 
distribution. Cell cycle and mitotic index analysis 
demonstrated that knocking-down Mre11 had no 
effect on mitotic index (Figure 6e), while silencing of 
Claspin significantly increased the mitotic index at 48h, 
specifically in cells treated with gemcitabine and AdΔ19K 
(Figure 6e). Importantly, Claspin and Mre11 knockdown 
resulted in significantly higher phospho-H2AX levels 
compared to non-targeted knockdown at both 48h and 
72h post-treatment with the gemcitabine and AdΔ19K 
combination (Figure 6f and S6). These results show that 
downregulation of either Mre11 or Claspin promote both 
DNA damage and cell death in the presence of concurrent 
treatment with gemcitabine and Ad∆19K. Taken together, 
these findings present a mechanism whereby adenovirus 
cooperates with DNA-damaging drugs to enhance cell 
killing while still promoting passage through the cell 
cycle, to complete the viral life cycle despite the high 
levels of unrepaired cellular DNA damage (Figure 7).
DISCUSSION
Pancreatic adenocarcinomas are always aggressive 
with high mortality rates and no effective treatments 
available for late stage disease. This malignancy has the 
lowest 5-year survival-rates globally (<5%). To date, no 
therapy has been reported to significantly prolong survival, 
including administration of nab-paclitaxel (Abraxane), 
cisplatin, 5-fluorouracil (5-FU), or gemcitabine [40]. 
Until now, the cytidine analogue gemcitabine has been 
the treatment of choice although drug-resistance develops 
rapidly. Gemcitabine is incorporated into DNA, blocking 
synthesis and causing DNA-strand breaks [31, 41] and has 
been evaluated in conjunction with several cytotoxic drugs 
acting through different mechanisms, including irinotecan 
that inhibits topoisomerase I [42, 43]. However, only 
limited improvements in survival, similar to gemcitabine 
alone, were reported for all combinations and the expected 
synergistic effects on tumour regression were not observed 
[40, 42]. Novel therapies with different mechanisms of 
action to overcome treatment-resistance are therefore 
urgently needed. Accumulating evidence has shown that 
oncolytic viruses may fulfil this role by acting on drug-
dependent cellular mechanisms to re-sensitize resistant 
cancers. For example, oncolytic adenoviral mutants 
enhanced overall responses to gemcitabine in clinical 
trials for pancreatic cancer [7] and caused regression 
of pancreatic tumours in xenograft models [10, 44, 45]. 
We previously reported that our engineered replication-
selective mutants, Ad∆∆ and Ad∆19K potently and 
specifically lysed cancer cells with deregulated G1/S cell 
cycle control and also increased cell killing in combination 
with DNA-damaging drugs in preclinical models of 
drug-insensitive pancreatic and prostate cancers [10, 11, 
24]. Ad∆∆- or Ad∆19K-infection in conjunction with 
gemcitabine, irinotecan, cisplatin, or docetaxel resulted in 
synergistic cell killing in cancer cell lines and prolonged 
time to tumour progression in vivo. The findings supported 
our hypothesis that deletion of the viral anti-apoptotic 
gene E1B19K was the cause of the significantly enhanced 
cell killing, suggesting that Ad∆19K could serve as a tool 
to identify cellular factors involved in drug-resistance or 
-sensitization for future therapeutic targeting.
In the current study, we demonstrate that Ad∆19K 
increases drug-induced DNA-damage and apoptotic death 
to a greater extent than Ad5, and that virus-mediated 
Figure 5: AdΔ19K inhibits drug-induced accumulation of Claspin through increased degradation and decreased 
synthesis. a. Immunoblot analysis of Claspin in PT45 cells, treated with 300ppc viruses ± 5nM gemcitabine (Gem) (left panel) or 5μM 
irinotecan (Iri) (right panel). Upper panels: Representative immunoblots of Claspin (250kDa) with Vinculin (130kDa) as loading control. 
Numbers indicate MW size marker (kDa). Bottom panels: Claspin protein levels were quantified by densitometric analysis, normalised 
to the loading control and expressed as fold-change relative to mock 24h (=1). Error bars represent S.E.M. of at least 3 independent 
experiments. b. Immunoblot analysis of phospho-Plk1 (T210) (pPlk1) and total Plk1 in PT45 cells, treated with 300ppc viruses ± 5nM 
gemcitabine (Gem) (left panel) or 5μM irinotecan (Iri) (right panel). Upper panels: Representative immunoblots of phospho- and total 
Plk1 (68kDa) with Vinculin (130kDa) as loading control. Numbers indicate MW size marker (kDa). Bottom panels: pPlk1 protein levels 
were quantified by densitometric analysis, normalised to total Plk1 and the loading control and expressed as fold-change relative to mock 
24h (=1). Error bars represent S.E.M. of 2 independent experiments. c. PT45 cells were treated with 300ppc of Ad5 or AdΔ19K ± 10nM 
gemcitabine (Gem). At 48hpi, 3μM of the protein synthesis inhibitor cycloheximide was added to study protein degradation. Cells were 
harvested at 0, 2, 4 and 6 hours post-cycloheximide treatment and prepared for immunoblot analysis of Claspin expression. Claspin protein 
levels were quantified by densitometric analysis, normalised to the loading control and expressed relative to the 0h time-point of each 
treatment (set to 1). The half-life was derived from plotting claspin protein levels against time post-cycloheximide treatment (min) and 
determining the time at which protein level was at 0.5. Error bars represent S.E.M. of 5 independent experiments. d. Claspin mRNA levels 
measured by qPCR in PT45 cells 24 and 48hpi, normalised to GAPDH internal control and expressed as fold-change relative to mock 24h 
(=1). Error bars represent S.E.M. of 3 independent experiments. a-d. *.p<0.05, **.p<0.01, ***.p<0.001 (one-way ANOVA with Bonferroni's 
multiple comparison test). e. PT45 cells were treated with 300ppc of AdΔ19K ± addition of 10nM gemcitabine (Gem). At 48hpi, 10μM of 
the proteasome inhibitor MG-132 was added to study protein synthesis. Cells were harvested at 0, 2 and 6 hours post-MG-132 treatment 
and prepared for immunoblot analysis of Claspin expression. Left panel: Representative immunoblot of Claspin (250kDa) with Vinculin 
(130kDa) as a loading control. Numbers indicate MW size marker (kDa). Right panel: Mean values of newly synthesised Claspin protein 
levels at 0, 2 and 6h post-MG-132 treatment. Claspin protein levels were quantified by densitometric analysis, normalised to the loading 
control and expressed relative to the 0h time-point of each treatment (set to 1). Error bars represent S.E.M. of 3 independent experiments. 
**.p<0.01 (two-way ANOVA with Bonferroni's multiple comparison test).
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checkpoint abrogation plays a key role. We previously 
demonstrated that suboptimal doses of gemcitabine 
stimulates viral uptake in pancreatic cancer cell lines [44], 
which was observed as increased number of E1A-positive 
cells in the presence of drug in this study. The increased 
number of virus-infected cells and the early E1A-gene 
expression in Ad∆19K-infected cells contributes to 
the enhanced cell killing while viral replication is not 
required. Increased E1A expression has previously been 
observed in the absence of the E1B19K gene, resulting in 
earlier lysis and enhanced viral spread in addition to E1A-
induced apoptosis [26, 46-48]. Taken together, our results 
suggest that E1A also augments drug-induced apoptosis 
in response to gemcitabine and irinotecan even when the 
drugs initially attenuate viral replication.
PT45 and MIAPaCa-2 cells have the genetic 
alterations that characterise pancreatic cancer including 
activating KRAS mutations, CDKN2A/p16 deletion, and 
inactivating TP53 mutations that result in deregulated cell 
cycle control [49]. Therefore, only limited increases in 
the S-phase population were noted after virus-infection 
and no enhancement of drug-induced S-phase arrest 
was observed, which has been proposed as a potential 
mechanism of synergy between gemcitabine and 
oncolytic adenoviruses [50-52]. In contrast, we found 
that simultaneous infection of gemcitabine-treated cells 
with either AdΔ19K or Ad5 increased the number of 
cells in mitosis through G2/M checkpoint abrogation. 
The combination-treated mitotic cells displayed a high 
degree of aberrations as a consequence of the extensive 
unrepaired DNA-damage caused by the drug-induced 
interruption of DNA synthesis and subsequent strand 
breaks. Ad5 is a potent inhibitor of the MRN-complex 
that activates the DNA damage repair response [22, 
23, 53, 54]. The inhibition is the result of E1A-induced 
expression of E4orf3, E4orf6 and E1B55K genes early 
during infection, targeting Mre11, Nbs1, Rad50 and 
p53 for sequestration and degradation. In this study, we 
found that the higher levels of unrepaired DNA damage 
was caused by adenovirus inactivation of the MRN-
mediated repair functions through mislocalization and 
degradation of Mre11, also in the presence of drugs that 
induce significant DNA-damage. In agreement with viral 
hindrance of the Mre11/MRN function, both Ad∆19K- and 
Ad5-infection decreased the potent activation of pChk1 
in drug-treated cells suggesting checkpoint abrogation. 
Carson et al. demonstrated that mislocalisation of Mre11 
by the viral E4orf3 protein was sufficient to prevent ATR 
signalling, but not concatemirization of viral DNA, which 
was prevented by E4orf6/E1B55K-mediated targeting of 
Mre11 for degradation [54]. Furthermore, the E4orf3-
dependent mislocalisation of Mre11 reduced ATR/Chk1 
signalling in response to the DNA-replication inhibitor 
hydroxyurea [54]. We conclude that the AdΔ19K-mediated 
mislocalisation and degradation of Mre11 in the presence 
of gemcitabine or irinotecan contribute to the attenuation 
of Chk1 phosphorylation, which subsequently would 
impair phosphorylation and recruitment of the homologous 
recombination factor Rad51 to DNA repair foci at stalled 
replication forks [55] (Figure 7). In addition, Mre11 is 
also critical for homologous recombination at stalled or 
collapsed replication forks [56], and its downregulation by 
Ad∆19K would further attenuate DNA repair resulting in 
increased accumulation of DNA damage.
Further evidence that the checkpoint was abrogated 
and cells with significant levels of unrepaired DNA-
damage progressed through the cell cycle in combination-
treated cells, is provided by our discovery that Ad∆19K 
Figure 6: Mre11 and Claspin knockdown enhance cell death and DNA damage in response to AdΔ19K and DNA-
damaging drugs. PT45 cells were transfected with siRNA against Claspin (siClas), Mre11 (siMre) or non-targeting siRNA (siNT), 
re-seeded and treated for use in cell viability assays, immunoblotting, Trypan Blue cell death assays, mitotic index analysis and viral 
genome amplification assays. Untreated cells were harvested at 48, 72, 96 and 120h post-transfection for immunoblot analysis to monitor 
Claspin and Mre11 knockdown. a and b. Upper panels: Representative immunoblots of a. Claspin (250kDa) and b. Mre11 (81kDa) 
with Vinculin (130kDa) as loading control. Numbers indicate MW size marker (kDa). Protein levels were quantified by densitometric 
analysis, normalised to the loading control and expressed as % protein knockdown relative to siNT. Error bars represent S.E.M. of at least 
4 independent experiments. Bottom panels: Sensitization ratios (EC50 of virus / EC50 of virus and drug) derived from cell viability assays 
72hpi (corresponding to 120h post-transfection). Error bars represent S.E.M. of at least 4 independent experiments. Drug cytotoxicity 
(%) ± S.E.M. was: 12.9±4.4% and 27.2±9% with 2nM and 5nM gemcitabine (Gem), respectively, and 18.3±8% with 5μM irinotecan (Iri) 
in siNT-transfected cells, 8.6±4.5% and 25.2±5.7% with 2nM and 5nM gemcitabine, respectively, and 25±6.5% with 5μM irinotecan in 
siClas-transfected cells, 29±6.5% and 47.9±1.1% with 2nM and 5nM gemcitabine, respectively, and 42.1±6.1% with 5μM irinotecan in 
siMre-transfected cells. c. Cell death assays using Trypan blue dye incorporation at 48 and 72hpi (corresponding to 96 and 120h post-
transfection, respectively). Error bars represent S.E.M. of 3 independent experiments. d. Viral genome amplification (Ad-E2A levels) at 
48hpi measured by qPCR. Viral DNA was normalized to input DNA (4h) and cellular GAPDH and expressed as fold-change relative to 
AdΔ19K siNT (=1). Error bars represent S.E.M. of 4 independent experiments. e. Mitotic index analysis at 48hpi in unsynchronised PT45 
cells stained with propidium iodide, a phospho-histone H3 antibody and an E1A antibody (for identification of infected cells). Dead cells, 
as identified from their incorporation of FVD, were excluded from the analysis. Error bars represent S.E.M. of 2 independent experiments. 
f. Immunoblot analysis of phospho-histone H2AX (Ser139) (pH2AX) 48hpi in siRNA-transfected PT45 cells treated with 300ppc viruses 
± 5nM gemcitabine (Gem). Upper panel: Representative immunoblot of pH2AX (15kDa) with Actin (42kDa) as loading control. Numbers 
indicate MW size marker (kDa). Bottom panel: pH2AX protein levels were quantified by densitometric analysis, normalised to the loading 
control and expressed as fold-change relative to mock 24h (=1). Error bars represent S.E.M. of 3 independent experiments. a-f. *.p<0.05, 
**.p<0.01, ***.p<0.001 (one-way ANOVA with Bonferroni's multiple comparison test).
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prevents drug-induced accumulation of the pChk1/ATR 
adaptor protein Claspin. Ad∆19K-mediated inhibition 
of Claspin synthesis and, to a lesser extent, increased 
degradation, enables checkpoint recovery and mitotic 
entry even in the presence of high levels of DNA 
damage. Interestingly, neither Ad5 nor Ad∆19K affected 
basal Claspin levels while both viruses induced pPlk1. 
However, only Ad∆19K caused significant inhibition of 
Claspin expression and increased pPlk1 activation in the 
presence of gemcitabine or irinotecan. It is possible that 
the higher levels of early viral genes in Ad∆19K-infected 
cells result in potent direct E1A- or E1B-binding to 
transcription-factors that regulate Claspin expression, or 
that viral E3- or E4-genes interfere with other regulatory 
elements of Claspin turnover. Both NF-κB and E2F1 were 
previously reported to regulate Claspin synthesis [57, 58] 
and interestingly, viral E1A can repress NF-κB-dependent 
transcription through suppression of IKK activity [59, 60]. 
We propose that the elevated E1A expression in Ad∆19K-
infected cells, followed by increased expression of 
additional early viral proteins including the E4 products, 
more potently prevented the accumulation of Claspin 
Figure 7: Schematic illustration of cellular mechanisms identified to play major roles in the enhanced cell killing 
in response to adenovirus and DNA-damaging drugs. The cytidine analogue gemcitabine is incorporated into DNA, blocks 
synthesis and directly causes DNA-strand breaks. Irinotecan, represented by its most potent metabolite SN38, inhibits topoisomerase 
I preventing completion of DNA-synthesis and causing DNA damage. E1A-expression in Ad∆19K-infected or Ad5-infected cells induces 
potent expression of E4orf3 and E4orf6 that prevent, together with E1B55K, the cellular DNA-damage response mainly by inactivating 
Mre11 and rendering the Mre11-Rad50-Nbs1 (MRN) repair complex non-functional (individual viral proteins not shown for simplicity). 
Degradation and mislocalisation of Mre11 results in direct attenuation of ATR/Chk1 phosphorylation and checkpoint abrogation preventing 
homologous recombination (HR). In addition, the high expression-levels of E1A/early viral genes in Ad∆19K-infected cells target Claspin 
for transcriptional downregulation and degradation that prevents full activation of Chk1 and reinforces checkpoint abrogation resulting in 
significant increases in deregulated entry into mitosis of cells with unrepaired damaged DNA. The end result is high levels of unrepaired 
DNA damage with synergistic and apoptotic death throughout the cell cycle.
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and the function of the DNA damage response compared 
to Ad5. Claspin has previously been reported to be a 
target of the E7 oncoprotein of human papilloma virus 
(HPV)-16 that increased the proteasomal degradation by 
deregulating components of the Aurora-A/Plk1/SCFβ-TrCP 
degradation machinery, thereby attenuating DNA damage 
responses and promoting mitotic entry [61]. Also, hepatitis 
B virus (HBV) X protein was shown to mediate Plk1 
activation, inducing Claspin degradation and attenuating 
both DNA repair and the checkpoint responses, thereby 
resulting in cell cycle progression and eventual death 
[62]. However, to our knowledge, adenovirus-mediated 
inhibition of Claspin activity had not been previously 
reported. Our findings reveal a potential novel mechanism 
whereby adenovirus destabilises Claspin, relaxes S-G2/M 
checkpoint activation, forces progression through the 
cell cycle in the presence of DNA damage and ultimately 
augments cell killing. It will be of great interest to 
determine whether adenovirus-mediated destabilisation 
of Claspin recruits similar mechanisms to those reported 
for HPV or HBV. Another possibility is that adenovirus-
mediated disruption of PP2A phosphatase activity by the 
viral E4orf4 protein [63, 64] could stabilize pPlk1 thereby 
inducing Claspin degradation, as PP2A was shown to de-
phosphorylate Plk1 in response to DNA damage [65].
Importantly, knockdown of Claspin or Mre11 
enhanced the cell death in combination-treated cells, 
strongly supporting our evidence for AdΔ19K-mediated 
downregulation of Claspin and Mre11 as major causes 
for the enhanced cell death (Figure 7). Mre11 knockdown 
potentiated DNA damage in combination-treated cells 
but had no effect on cell cycle distribution or viral DNA 
replication. We conclude that downregulation of Mre11 
contributes to the observed apoptotic cell death that 
occurred throughout the cell cycle. Knockdown of Claspin 
also increased DNA damage in combination-treated 
cells, with no effects on viral DNA replication, however 
the number of cells entering mitosis increased. These 
results suggest that the enhanced cell death observed 
when Claspin is downregulated might be a result of both 
increased DNA damage and mitotic entry in combination-
treated cells, with subsequent mitotic aberrations.
In conclusion, our data strongly point toward a role 
for the potent earlier E1A expression in the absence of 
the E1B19K-gene, in promoting the expression of the 
viral E1B and E4 genes that attenuate the DNA damage 
response, as essential for the synergistic cell killing. 
Although less pronounced, mitotic aberrations and DNA 
damage were also observed with Ad5 infection. However, 
Ad∆19K greatly attenuated drug-induced Claspin 
expression, which was not significantly reduced in the 
presence of Ad5. We suggest that both aberrant mitosis 
and enhanced apoptotic death throughout the cell cycle 
due to high levels of DNA damage is required for the 
synergistic cell killing. Our findings have revealed novel 
cellular targets that are deregulated by adenovirus to 
subvert the cellular defence against both viruses and other 
cytotoxic agents. We propose that exploiting these factors 
in combination with DNA-damaging drugs, improved anti-
cancer therapeutics could be developed resulting in greatly 
enhanced tumour cell killing. Oncolytic adenoviruses 
could be designed to synergise with DNA-damaging drugs 
by incorporating the E1B19K-deletion in combination 
with inhibitors or si/shRNA that target pChk1/Claspin and 
Mre11/Rad51.
MATERIALS AND METHODS
Cell lines and culture conditions
The human pancreatic adenocarcinoma cell lines 
PT45 (Prof H. Kalthoff, Kiel, Germany) and MIAPaCa-2 
(ATCC, VA) are derived from primary PDAC tumours. 
The cell lines were STR-profiled (LGC Standards, UK 
and Cancer Research UK) and verified to be identical to 
the profiles reported by the suppliers and to the original 
vial. Cells were grown at 37°C and 5% CO2 in Dulbecco 
modified Eagle’s medium (DMEM) supplemented with 
10% Fetal Bovine Serum (FBS) and 1% penicillin and 
streptomycin (Penicillin 10000 units/ml, Streptomycin 
10mg/ml; P/S) (all purchased from Sigma-Aldrich, MO). 
DMEM contained 4.5g/L glucose, L-glutamine, sodium 
pyruvate and sodium bicarbonate. In all experiments cells 
were seeded in 10% FBS/1% P/S DMEM.
Viruses and infections
Both wild-type virus Ad5 and the mutant Ad∆19K 
were generated from the species C wild-type adenovirus 
type 5 plasmid pTG3602 (a gift from Dr Majid Mehtali, 
Transgéne, Strasbourg, France), produced, purified and 
characterised as previously described [11, 24]. Ad∆19K 
is deleted in the anti-apoptotic E1B19K gene (Ad∆19K). 
The viral particle (vp) to infectious units (plaque-forming 
units; pfu) was 28 and 12 vp/pfu for Ad5 and Ad∆19K, 
respectively. All infections were performed in serum-free 
DMEM -/+ the indicated doses of viruses and 2h later the 
medium was replaced with 10% FBS/1% P/S DMEM -/+ 
the indicated dose of drug(s).
Trypan blue inclusion cell death assay
PT45 and MIAPaCa-2 cells were infected with 
300ppc of Ad5 or AdΔ19K -/+ addition of 5nM (PT45) 
or 20nM (MIAPaCa-2) gemcitabine (Gemzar; Eli 
Lilly, Indianapolis, IN) or 5μM irinotecan (Campto, 
Hospira UK Limited, Leamington Spa, UK). At 
the indicated times cells were trypsinised and cell 
suspension was mixed with 0.4% Trypan Blue dye 
(Bio-Rad Laboratories, Inc, CA) at 1:1 ratio and 10μl 
in duplicates were loaded onto a dual-chambered 
counting slide (Bio-Rad). Cell count and viability were 
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assessed using a TC20™ automated cell counter (Bio-
Rad). Percentage cell viability was recorded and used to 
calculate cell death.
Cell viability assays
Cell viability assays were performed as described 
previously [11]. Cells were infected with Ad5 or Ad∆19K 
-/+ addition of gemcitabine or irinotecan in 2% FBS/1% 
P/S DMEM. Drug concentration was fixed at doses 
previously determined to kill 20-40% of cells. Cells 
were assayed 72h later using the 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium assay (Promega, Southampton, UK) 
to quantify live cells as an indirect measurement of 
cell death. Dose–response curves were generated to 
determine the concentration of each agent killing 50% 
of cells (EC50) using untreated cells or cells treated with 
one agent only as controls. Each data point was generated 
from triplicate samples and experiments repeated at least 
three times.
Cleaved caspase-3 apoptotic assay
PT45 cells were infected with 300ppc of Ad5tg 
or AdΔ19K -/+ addition of 5nM gemcitabine. Where 
indicated, 25μM of the pan-caspase inhibitor Calbiochem® 
Z-VAD(OMe)-FMK (5mM in dimethyl sulfoxide 
(DMSO); Millipore, MA) was added simultaneously 
with gemcitabine or staurosporine. Mock-infection and 
16h treatment at 1μM with the apoptosis-inducing agent 
staurosporine (1mM in DMSO; Sigma-Aldrich), were 
used as negative and positive controls, respectively. At 
72hpi cells were harvested, fixed and stained using the 
FITC Active Caspase-3 Apoptosis Kit (BD Biosciences 
Pharmingen, CA) according to the manufacturer’s 
guidelines. Additionally, cell pellets were re-suspended 
in 250μl of PBS containing 50μg/ml of propidium iodide 
(PI) (1mg/ml in water; Thermo Fisher Scientific, CA) and 
100μg/ml of ribonuclease A (RNAse A) (33mg/ml in Tris-
HCl/glycerol; Sigma-Aldrich) and incubated for 30min at 
22°C. Flow-cytometric data acquisition was performed 
using BD CellQuest™ software operated on a BD 
FACSCalibur instrument (both from Becton Dickinson, 
NJ). PI and FITC signals were detected in the FL-3 and 
FL-1 channel, respectively, of the 488nm argon laser. 
Dot plots of Side Scatter (SSC-H) vs Forward Scatter 
(FSC-H) were used to exclude debris, followed by doublet 
exclusion using the area and width of the FL2 channel. 
Acquisition stopped when 20000 events were acquired in 
the doublet-exclusion gate. Cell-cycle specific apoptosis 
was measured by plotting the FL1-H channel, where FITC 
was detected, against the FL3-H channel, where PI was 
detected, and gates for apoptotic cells with DNA content 
of 2N (G1-phase), 2-4N (S-phase), 4N (G2/M-phase) and 
>4N (polyploid), where applied. Post-acquisition data 
analysis was performed using the FlowJo v7.6.5 software 
(Tree star, Inc, OR).
Cell synchronisation
PT45 cells were treated with 2.5mM thymidine 
(100mM in water; Alfa Aesar, MA) for synchronisation 
in early S-phase. 24h after treatment, cells were released 
from the thymidine block by washing twice with PBS. 
Cells were immediately infected with 300ppc of viruses 
-/+ 5nM gemcitabine.
Cell cycle and mitotic index analysis
PT45 cells were infected with 300ppc of viruses -/+ 
5nM gemcitabine. At the indicated times post-infection, 
supernatant and cells were harvested, washed with PBS 
and incubated with 250μl of the fixable viability dye 
(FVD) eFluor® 506 (eBioscience, CA) diluted 1:1000 in 
PBS. Following a 30min incubation at 4ºC, cells were 
washed in PBS and fixed with cold 70% ethanol (30min, 
4ºC). All centrifugations henceforth were performed at 
2000rpm for 3min. Cells were washed with 1ml of 1% 
FBS/PBS and permeabilised using cold 0.25% Triton 
X-100 diluted in 1% FBS/PBS. Following a 10min 
incubation at 4ºC, cells were centrifuged and incubated in 
100μl of rabbit polyclonal anti-phospho-histone H3 (S10) 
(Abcam, UK) and mouse monoclonal anti-E1A antibodies 
diluted in 1% FBS/PBS (30min, 22°C). Following two 
washes in 2ml of 1% FBS/PBS, cells were incubated 
in 100μl of goat anti-rabbit Alexa Fluor® 488 and anti-
mouse Alexa Fluor® 647 IgG (H+L) antibodies (Life 
Technologies, Thermo Fischer Scientific, UK) diluted in 
1% FBS/PBS (30min, 22°C). Cells were then washed with 
3ml of 1% FBS/PBS and incubated in 200μl of PI (50μg/
ml)/RNAse A (100μg/ml) solution (30min, 22°C). Cells 
were immediately acquired using the BD FACSDiva™ 
software operated on the BD LSRFortessa™ cell analyzer 
(both from Becton Dickinson). PI and Alexa Fluor® 488 
signals were detected in the B695/40 and B5300/30 
filters, respectively, of the 488nm blue laser. FVD eFluor® 
506 and Alexa Fluor® 647 signals were detected in the 
V525/50 filter of the 405nm violet laser and R670/14 
filter of the 640nm red laser, respectively. Cell debris and 
doublets were excluded, followed by gating of live cells 
and acquisition of 20000 events. Data were analyzed using 
the FlowJo v7.6.5 software.
For cell cycle analysis with PI only, PT45 and 
MIAPaCa-2 cells were infected, treated and harvested 
as specified and fixed with cold 70% ethanol (30min, 
4°C). Cells were pelleted, washed with 1ml of PBS and 
incubated in 300μl of PI (50μg/ml)/RNAse A (100μg/
ml) solution (30min, 22°C). Immediately after staining, 
cells were analysed using a BD FACSCalibur instrument. 
Cell debris and doublets were excluded and 20000 events 
were acquired. PI fluorescence was detected using the FL3 
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channel of the 488nm argon laser. Data were analyzed 
using the FlowJo v7.6.5 software.
Immunofluorescence microscopy analysis
PT45 cells were seeded on coverslips (Menzel-
Gläser, Germany), treated as specified and at the indicated 
times post-infection processed as follows:
Methanol fixation method
Cells were fixed in 100% ice-cold methanol (20min, 
4°C), followed by 20min blocking in 5% FBS/PBS and 
incubation (overnight, 4°C) in mouse monoclonal anti-
Aurora-A (IAK-1) (BD Biosciences) and rabbit polyclonal 
anti-α-Tubulin (Abcam) antibodies diluted in 5% FBS/
PBS. Cells were washed three times in PBS and incubated 
(1h, 22°C) in goat anti-mouse AlexaFluor® 488 and anti-
rabbit AlexaFluor® 594 IgG (H+L) antibodies (both from 
Life Technologies) diluted in 5% FBS/PBS.
Paraformaldehyde fixation method
Cells were fixed (10min, 22°C) in 4% 
paraformaldehyde/PBS (made from 16%(w/v) formaldehyde; 
TAAB, UK), followed by permeabilization (10min, 22°C) 
in Triton buffer (0.5% Triton X-100, 20mM Hepes KOH 
pH7.9, 50mM NaCl, 3mM MgCl2, 300mM Sucrose). 
Cells were blocked in 0.05% Tween-20/3% BSA/PBS 
(15min, 22°C) and incubated (overnight, 4°C) in primary 
antibodies diluted in blocking buffer. Antibodies used: 
mouse monoclonal anti-Ad-DBP (37.3) (a gift from K. 
Benihoud, Institut Gustave Roussy, Villejuif, France), 
rabbit polyclonal anti-phospho-histoneH2A.X (Ser139) 
(Cell Signalling Technology, MA), mouse monoclonal anti-
E1A and/or rabbit polyclonal anti-Mre11 (Genetex Inc., 
CA). Coverslips were washed twice in blocking buffer and 
incubated (1h, 22°C) in secondary antibodies (goat anti-
mouse or anti-rabbit AlexaFluor® 594 and/or goat anti-
mouse AlexaFluor® 488) diluted in blocking buffer.
Mounting and analysis
Coverslips were washed in PBS and distilled 
water and were allowed to dry (30min, 22°C) before 
mounting on slides (ESCO Optics, NJ) using the ProLong 
Gold antifade reagent with DAPI (Life Technologies, 
Thermo Fisher Scientific). Slides were analysed using a 
Zeiss Axioplan epifluorescent microscope. Images were 
acquired using the confocal laser scanning microscope 
Zeiss LSM510 META.
PT45 histone H2B-mCherry stable cell line 
generation and time-lapse microscopy
PT45 cells were transfected with 5μg of 
histoneH2B-mCherry construct (a gift from Dr Spiros 
Linardopoulos, The Institute of Cancer Research, London, 
UK) using 16μl Lipofectamine™ 2000 (Life Technologies 
Thermo Fisher Scientific), according to the manufacturerʼs 
instructions. 24h later cells were harvested, washed in PBS 
and fluorescently sorted using the BD FACSAria™ cell 
sorter (Becton Dickinson) based on mCherry expression 
(detected in the YG610/20-A filter of the yellow-green 
561nm laser). The PT45 histoneH2B-mCherry cells were 
fluorescently sorted several times until more than 90% 
of cells expressed mCherry. For time-lapse microscopy 
PT45 histoneH2B-mCherry cells were synchronised 
and infected as detailed above. 2hpi the medium was 
replaced with 10% FBS/Leibovitz’s L15 medium (Life 
Technologies) -/+ 5nM gemcitabine. 24hpi cells were 
subjected to a 72h time-lapse imaging by phase-contrast 
and fluorescence microscopy using a Zeiss Axiovert 
200M fluorescence microscope. Images from 3 different 
fields per condition were acquired every 15min from 24 
to 96hpi. Data were analysed using AxioVision Rel. 4.9.1 
(Carl Zeiss, Germany) and NIH ImageJ software.
TUNEL assay
PT45 cells were infected with 300ppc of viruses 
-/+ 10nM gemcitabine. 72hpi cells were harvested, fixed 
and stained using the APO-BrdU kit (BD Biosciences 
Pharmingen) according to the manufacturer’s guidelines. 
Flow-cytometric data acquisition was performed using 
BD CellQuest™ software operated on a BD FACSCalibur 
instrument (both from Becton Dickinson). FITC 
fluorescence was detected in the FL-1 of the 488nm argon 
laser. Cell debris and doublets were excluded and 20000 
events were acquired. Post-acquisition data analysis was 
performed using the FlowJo v7.6.5 software.
Immunoblotting
PT45 and MIAPaCa-2 cells were infected and 
treated as specified, and harvested at the indicated 
times. Cells were lysed in RIPA buffer (50mM Tris 
pH 8.0, 150mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with protease 
inhibitor cocktail and PhosSTOP phosphatase inhibitor 
(Roche Diagnostics, Switzerland). Cell lysates were 
incubated on ice (15min), centrifuged (15min, 16100xg, 
4°C) and quantitated for protein using the Bio-Rad 
Protein assay (Bio-Rad) according to the manufacturer’s 
guidelines. Cell lysates were mixed with 2X sample 
Laemmli buffer (0.125M Tris-HCl pH6.8, 20% glycerol, 
4% SDS, 0.01% bromophenol blue and freshly-added 10% 
β-mercaptoethanol) and incubated for 5min at 95ºC. Equal 
amounts (typically 30-60μg) of protein were resolved by 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
using the Mini-PROTEAN® Tetra cell system (Bio-Rad). 
Proteins were then transferred to nitrocellulose membranes 
(Hybond-ECL, GE Healthcare, UK) using the Trans-
Blot® SD semi-dry electrophoretic transfer cell (Bio-Rad) 
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or the Mini Trans-Blot® electrophoretic transfer cell system 
(Bio-Rad). Membranes were incubated (overnight, 4°C) in 
the following primary antibodies: rabbit polyclonal anti-
phospho-histone H2A.X Ser139, rabbit polyclonal anti-
α-Tubulin, goat polyclonal anti-Actin (C-11) (SantaCruz 
Biotechnology, Inc; TX), rabbit polyclonal anti-phospho-
Chk1 Ser296 (133D3) (Cell Signalling Technology), rabbit 
polyclonal anti-Chk1 (Cell Signalling Technology), mouse 
monoclonal anti-Vinculin (SPM227) (Abcam), rabbit 
polyclonal anti-Mre11, rabbit polyclonal anti-Claspin 
(Cell Signalling Technology), rabbit polyclonal anti-
phospho-Plk1 Thr210 (Enzo Life Sciences, UK), mouse 
monoclonal anti-Plk1 (Abcam) and mouse monoclonal 
anti-β-Tubulin (SAP.4G5) (Abcam). Membranes were 
washed in 0.1% Tween-20/TBS, and incubated (1h at 
22°C or 2h at 4°C) in polyclonal anti-goat, mouse or rabbit 
immunoglobulins/HRP (Dako). Immunodetection was 
performed using enhanced chemiluminescence substrate 
ECL and ECL-Plus (PerkinElmer). Protein bands were 
visualised on X-ray films (FujiFilm) or using the G:Box 
iChemi-XT imaging system (Syngene, UK) and quantified 
by densitometric analysis using the NIH ImageJ software.
mRNA analysis by reverse transcriptase qPCR
PT45 cells were infected with 300ppc of viruses, 
treated with 5nM gemcitabine and harvested (excluding 
supernatant) at the indicated times. RNA was extracted 
using the RNeasy Mini Kit (Qiagen, Netherlands) 
according to the manufacturer's instructions and purified 
from contaminating DNA using the DNA-free™ kit 
(Ambion®, Life Technologies, CA) according to the 
manufacturer's instructions. 1μg of RNA was reversed 
transcribed in a 50μl reaction containing 1x TaqMan® 
Reverse Transcription Buffer, 5.5mM MgCl2, 500μM 
deoxyNTPs mixture, 2.5μM random hexamers, 0.4units/
μl RNase inhibitor and 1.25units/μl MultiScribe® Reverse 
Transcriptase (all from Applied Biosystems, Thermo Fisher 
Scientific). Reverse transcription was performed using a 
DNA Engine Dyad® Peltier thermal cycler (MJ Research) 
by incubating at 25°C for 10min, followed by 30min 
incubation at 48°C and a 5min incubation at 95°C. 20ng of 
complementary DNA (cDNA) were used in qPCR analysis 
of viral E1A and Penton genes and the cellular Claspin 
with GAPDH as internal control. qPCR using the standard 
curve method (Applied Biosystems 7500 Instrument) was 
performed with SYBR® Green PCR master mix (Applied 
Biosystems) and 200nM of the following primers: E1A 
5'-TGCCAAACCTTGTACCGGA-3' (forward) and 
5'-CGTCGTCACTGGGTGGAAA-3' (reverse), Penton 
5'-GATCGGAAAACCTCTCGAGAAA-3' (forward) 
and 5'-CGTAGGAGGGAGGAGGACCTT-3' (reverse), 
Claspin 5'-ACAGTGATTCCGAAACAGA-3' (forward) 
and 5'-TGCTCCTCGGCACTGTCATA-3' (reverse). 
Melting (dissociation) curves for each primer set were 
generated for primer quality control.
siRNA transfections
PT45 cells were left untransfected or transfected 
with 25nM of siGENOME non-targeting (NT) siRNA 
#1 control (D-001210-01-05), siGENOME SMARTpool 
Claspin (CLSPN) siRNA or siGENOME SMARTpool 
MRE11A siRNA, using DharmaFECT1 transfection 
reagent (all purchased from Dharmacon, GE Healthcare) 
according to the manufacturer’s instructions. siRNA 
sequences: siGENOME SMARTpool CLSPN (D-005288-
01/02/03/04) ‘5-GGAAAUACCUGGAGGAUGA-3’, 
‘5-GCAGAUGGGUUCUUAAAUG-3’, ‘5-GGACG 
UAAUUGAUGAAGUA-3’, ‘5-GAAUUUAUAUGCUG 
GGAAA-3’ and siGENOME SMARTpool MRE11A 
(D-009271-01/02/03/04) ‘5-GAUGAGAACUC 
UUGGUUUA-3’, ‘5-GAAAGGCUCUAUCGAAUGU-3’, 
‘5-GCUAAUGACUCUGAUGAUA-3’, ‘5-GAGUAUA 
GAUUUAGCAGAA-3’. After 6h medium was replaced 
with 10% FBS/1% P/S DMEM. 24-32h later non-
transfected, siNT-, siCLSPN- and siMRE11-transfected 
cells were harvested, counted and re-seeded in 96-well 
plates for use in cell viability assays or 6-well plates for 
use in immunoblotting, trypan blue cell death assays, 
mitotic index analysis and/or viral genome amplification 
assays.
Viral genome amplification
PT45 cells were infected with 300ppc of viruses, 
treated with 5nM gemcitabine and harvested (excluding 
supernatant) at 4, 24, 36, 48 and 72hpi. Cell suspension 
was pelleted, snap-frozen and stored at -80ºC. DNA 
was extracted using the QIAamp DNA Blood Mini Kit, 
according to the manufacturer’s instructions (Qiagen) and 
used for quantitative PCR (qPCR) analysis as previously 
described [10].
Quantification of E1A protein expression 
by flow cytometry
PT45 and MIAPaCa-2 cells were infected with 
300ppc (PT45) or 100ppc (MIAPaCa-2) of viruses -/+ 
5nM (PT45) or 10nM (MIAPaCa-2) gemcitabine. At 
the indicated times cells were harvested (excluding 
supernatant) and 0.5-1x106 cells/ml were resuspended 
in ice-cold 3% BSA/1% sodium azide/PBS, pelleted and 
fixed in 0.5ml 100% methanol (10min, -20°C). Cells 
were washed twice in 1% BSA/PBS and permeabilised in 
0.5ml of 0.5% Triton-X100/PBS (15min, 22°C), followed 
by wash in 0.1% Triton/PBS and incubation with mouse 
monoclonal anti-E1A (M58) antibody (Labvision, Thermo 
Fisher Scientific) diluted in 3% BSA/PBS (30min, 22°C). 
Cells were washed once with PBS and incubated with 
anti-mouse monoclonal FITC-conjugated antibody (Dako, 
Denmark) diluted in 3% BSA/PBS (30min, 22°C). Cells 
were washed twice in PBS, resuspended in 3% BSA/1% 
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sodium azide/PBS and analysed by flow cytometry using 
a BD FACSCalibur instrument. Cell debris was excluded 
and 20000 events were acquired. FITC was detected using 
the FL1 channel of the 488nm argon laser. Data were 
analyzed using the FlowJo v7.6.5 software.
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